|Other Names||Midkine, MK, Amphiregulin-associated protein, ARAP, Midgestation and kidney protein, Neurite outgrowth-promoting factor 2, Neurite outgrowth-promoting protein, MDK, MK1, NEGF2|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Developmentally regulated, secreted growth factor homologous to pleiotrophin (PTN), which has heparin binding activity. Binds anaplastic lymphoma kinase (ALK) which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate (IRS1), followed by the activation of mitogen-activated protein kinase (MAPK) and PI3-kinase, and the induction of cell proliferation. Involved in neointima formation after arterial injury, possibly by mediating leukocyte recruitment. Also involved in early fetal adrenal gland development (By similarity).|
|Tissue Location||Expressed in various tumor cell lines. In insulinoma tissue predominantly expressed in precancerous lesions|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Midkine is a retinoic acid-responsive, heparin-bindinggrowth factor expressed in various cell types during embryogenesis.It promotes angiogenesis, cell growth, and cell migration. Midkineis also expressed in several carcinomas, suggesting that it mayplay a role in tumorigenesis, perhaps through its effects onangiogenesis (summary by Reynolds et al., 2004 [PubMed15197188]).
Ferreira, R.C., et al. Nat. Genet. 42(9):777-780(2010)Kerzerho, J., et al. J. Immunol. 185(1):418-423(2010)Yao, X., et al. Acta Pharmacol. Sin. 31(5):629-637(2010)Zhang, Z.H., et al. Cell Prolif. 43(2):184-194(2010)Rice, G.E., et al. J. Exp. Clin. Cancer Res. 29, 62 (2010) :
If you have any additional inquiries please email technical services at email@example.com.